Guardant Health (NASDAQ:GH) Announces Earnings Results

Guardant Health (NASDAQ:GH) posted its quarterly earnings results on Thursday. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15), Zacks reports. The business had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. Guardant Health updated its FY 2025 guidance to EPS.

Guardant Health Stock Performance

Shares of NASDAQ GH opened at $42.87 on Friday. The firm has a market capitalization of $5.30 billion, a price-to-earnings ratio of -12.04 and a beta of 1.32. The stock has a 50 day moving average price of $40.19 and a 200 day moving average price of $31.59. Guardant Health has a 52-week low of $15.81 and a 52-week high of $50.89.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Stifel Nicolaus lifted their target price on Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a report on Friday. Raymond James reaffirmed an “outperform” rating and issued a $59.00 target price (up from $39.00) on shares of Guardant Health in a report on Friday. The Goldman Sachs Group lifted their target price on Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a report on Friday. JPMorgan Chase & Co. boosted their price objective on Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Barclays began coverage on Guardant Health in a research note on Thursday, January 23rd. They set an “overweight” rating and a $60.00 price objective on the stock. Eighteen analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $44.78.

Insider Activity at Guardant Health

In related news, Director Musa Tariq sold 2,320 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the sale, the director now owns 2,676 shares in the company, valued at approximately $93,660. The trade was a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders sold 2,768 shares of company stock worth $98,798. Company insiders own 5.50% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.